{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000107","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.016223+00:00","generated_at":"2026-06-12T02:21:45.217230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gossamer Bio Q2 net loss $42.5M; raises $212M in July private placement","bullets":["Net loss $42.5M ($0.45/share) vs $56.5M ($0.74) in Q2 2022; R&D expenses decreased to $36.3M.","Cash, equivalents & marketable securities $162.1M as of June 30; pro forma for July placement total $374M.","Phase 3 PROSERA study of seralutinib in PAH expected to start in Q3 2023; primary endpoint 6MWD at week 24.","Additional TORREY open-label extension data expected in Q4 2023 or Q1 2024.","July private placement raised ~$212M gross from sale of shares and warrants to institutional investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000107","json":"https://secwatch.observer/filing/0001728117-23-000107.json","markdown":"https://secwatch.observer/filing/0001728117-23-000107.md","text":"https://secwatch.observer/filing/0001728117-23-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/0001728117-23-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/goss-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:21:45.217230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aad7e6993fa074b38c1b807f117327c63671ffd6","claim":"Gossamer Bio, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share, EPS $0.45 per share.","evidence_excerpt":"On August 8, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/0001728117-23-000107-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share"},{"label":"EPS","value":"$0.45 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}